Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL: Cipaglucosidase Alfa/Miglustat vs Alglucosidase Alfa in Late-onset Pompe Disease
NCT03729362Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Replacement Enzymes
- Countries
- 24
01
Overview
A Phase 3 trial of cipaglucosidase alfa in Pompe disease, sponsored by Amicus Therapeutics. Started Dec 2018; status: completed.
02
Drugs
cipaglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT03729362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729362.